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Abstract
This study aimed to compare the clinicopathologic characteristics and oncologic outcomes of papillary thyroid cancer (PTC) patients
according to sex. Then, we validated prognostic variables to determine whether sex is a signiﬁcant prognostic factor for PTC.
Between January 2007 and December 2010, 1232 men and 7276 women PTC patients underwent surgery. The patient
characteristics and 5-year oncologic outcomes were compared. The stepwise Cox proportional hazards model determined the
signiﬁcance of survival variables.
Men PTC patients had more lymph node (LN) metastases than women, both in the total (P< .0001) and hemithyroidectomy
(P< .0001) patients. Men and women showed similar 5-year recurrence-free survivals, both in total (P= .815) and hemithyroidectomy
(P= .148) patients. The tumor size and the number of positive central nodes were associated with tumor recurrence, but not sex.
Sex was not an independent prognostic factor for tumor recurrence. Multicenter clinical studies with long-term follow-ups are
needed to validate these results.
Abbreviations: CCND = central compartment neck dissection, CI = conﬁdence interval, CT = computed tomography, DSS =
disease-speciﬁc survival, DTC = differentiated thyroid cancer, FNAB = ﬁne needle aspiration biopsy, FTC = follicular thyroid cancer,
thyroid cancer, HR = hazard radio, LN = lymph node, OS = overall survival, PMC = papillary microcarcinoma, pN1a = pathological
N1a, PTC = papillary thyroid cancer, RAI = radioactive iodine, RFS = recurrence-free survival, Tg = thyroglobulin, TSH = thyroid-
stimulating hormone, US = ultrasonography.
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Sex is an important factor related to the pathogenesis, diagnosis, and
prognosisofmanydiseases.[1] Sexdisparitieshavebeendiscovered in
various cancers, and can easily be observed in sex-speciﬁc organs
such as the breast, ovary, uterus, and prostate. However, differences
in the incidence and/or prognosis are also shown in some sex-shared
sites, including the thyroid, lung, and skin.[2,3]
The thyroid cancer incidence has increased worldwide over the
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1It accounts for 1% of all cancers worldwide,[4] with a 6.6%
annual percent change in the United States from 1997 to 2009.[5]
The increased incidence is predominantly observed for tumors
with papillary histology, with no signiﬁcant changes seen in cases
of follicular, medullary, or anaplastic histology. The increase
includes mainly papillary microcarcinomas (PMCs), deﬁned as
tumors <1cm, although the incidence of large tumors has also
increased.[6,7]
With the rising incidence, thyroid cancer is currently the
seventh most common malignancy in women; however, it is not
among the most common 15 cancers in men. The 2002
GLOBOCAN database reported 103,589 female thyroid cancer
cases worldwide, compared with 37,424 male cases, representing
a female-to-male ratio of >2:1.[8] This sex disparity appears
dominantly in differentiated thyroid cancer (DTC), such as
papillary thyroid cancer (PTC) and follicular thyroid cancer
(FTC), the incidence of which is 3-times higher in women than in
men.[9]
Patients with thyroid cancer have a favorable prognosis, with
the 10-year survival generally reported to exceed 90%. However,
multiple studies have reported that men have a worse prognosis
than women.[10–12] From the analysis of large retrospective
uncontrolled studies, sex has been identiﬁed as a signiﬁcant
prognostic factor for thyroid cancer along with other parameters
such as age, tumor size, histologic type, multicentricity,
extrathyroidal extension, and lymph node (LN) metastases.[10,12]
Among the several staging classiﬁcations for thyroid cancer, the
Age, Metastases, Extent and Size and the European Organization
Kim et al. Medicine (2019) 98:19 Medicinefor the Research and Treatment of Cancer criteria include sex as a
variable.[13,14]
Considering the sex differences in the incidence patterns,
aggressiveness, and prognosis of thyroid cancer, the present study
aimed to ﬁrst identify and compare recent trends in clinicopath-
ologic characteristics and oncologic outcomes of both male and
female PTC patients. Second, we aimed to validate prognostic
variables to determine whether sex is a signiﬁcant prognostic
indicator for PTC.2. Methods
2.1. Patients
To discover recent trends of PTC, medical records of patients
who were diagnosed with PTC from January 2007 to December
2010 were reviewed. A total of 8508 PTC patients, including
1232 male patients (14.5%) and 7276 female patients (85.5%),
underwent thyroid surgery at the Department of Surgery in
Yonsei University College of Medicine. Among them, hemi-
thyroidectomy was performed for 250 male and 1501 female
patients. Initially, comparative analyses were performed for all
patients, followed by subgroup analyses among the hemi-
thyroidectomy patients, according to sex. All procedures
performed in this study were in accordance with the ethical
standards of the Institutional Review Board of Yonsei University
Health System (4–2016–0538) and with the 1964 Declaration of
Helsinki and its later amendments or comparable ethical
standards.2.2. Preoperative work-up
The preoperative patient work-up included physical examina-
tion, high-resolution staging ultrasonography (US), and neck
computed tomography (CT). Thyroid nodules were diagnosed
preoperatively based on US-guided ﬁne needle aspiration biopsy
(FNAB). In patients with DTC, the size and location of tumor,
degree of extrathyroidal extension, nodal involvement, and other
abnormal ﬁndings in the neck were complementarily evaluated
by preoperative US and neck CT.[15] If a patient had clinically
palpable LNs or a LN with a suspicious appearance on
preoperative US, FNAB was performed for the LN. The presence
of LN metastasis was determined by ultrasonography-guided
FNAB or by the thyroglobulin (Tg) levels in the FNAB washout
ﬂuid (FNA-Tg >10ng/mL, >the mean + 2SD of the FNA-Tg
measured in node-negative patients, or >serum-Tg) from the
LN.[16] Meanwhile, LN micrometastases were deﬁned as
metastatic deposits within a LN of <2mm in diameter, which
are rarely detected by US (clinical N0).[17]
2.3. Surgery
The criteria for the extent of surgery were determined in
accordance with the American Thyroid Association guidelines.[18]
Hemithyroidectomywas indicated if the following conditionswere
satisﬁed: patient age <45 years, a single lesion <1cm in size, no
deﬁnite extrathyroidal invasion, no LNmetastasis on preoperative
imaging studies, no personal history of the disease in the head or
neck, and no ﬁrst-degree family history of DTC. In all other cases,
total thyroidectomy was indicated.
Prophylactic ipsilateral central compartment neck dissection
(CCND) was conducted in all patients. The central compartment
LNs consist of the level 6 LNs (pretracheal, prelaryngeal, and2paraesophageal LNs), which include the LNs from the hyoid
bone superior to the suprasternal notch inferiorly. On each side,
the lateral boundary is limited by the medial border of the carotid
sheath. For patients diagnosed with metastatic thyroid cancer in
the lateral neck, neck dissection of levels IIa, III, IV, and VB was
performed. The surgery followed the approaches of modiﬁed
radical neck dissection type III for PTC, sparing the sternoclei-
domastoid muscle, spinal accessory nerve, and internal jugular
vein. The LNs at levels IIB and VA were not routinely
dissected.[19,20]
All patients were administered with levothyroxine for thyroid-
stimulating hormone (TSH) suppression immediately postopera-
tively. Radioactive iodine (RAI) ablation was performed based on
each patient’s stage and risk factors, according to American
Thyroid Association guidelines, at 4 to 12 weeks after surgery.[18]
These patients underwent post-therapy whole-body scans and
diagnostic whole-body scans 2 to 5 days after RAI ablation, and
abnormal RAI uptakes were investigated.[21]
2.4. Outcome assessment
To evaluate oncologic outcomes, the TSH-suppressed serum Tg
concentration was measured annually, and all patients under-
went regular follow-up US. Patients with evidence of recurrence
or distant metastasis were assessed using other imaging
modalities, such as neck CT and/or positron emission tomogra-
phy-CT. Regional neck node recurrence was conﬁrmed by US-
guided FNAB.
Overall survival (OS) was deﬁned as the time from the date of
initial surgery to the date of the last follow-up or death.
Recurrence-free survival (RFS) was deﬁned as the time from the
surgery to the date of detection of the ﬁrst recurrence on imaging.2.5. Statistical analysis
Categorical data are reported as the rates and proportions, while
the median and ranges were calculated for continuous data.
Differences in continuous variables between men and women
were compared using the Mann–Whitney U test or the Student t
test, and differences in categorical variables were compared with
the chi-square test or Fisher exact test, as appropriate. Patient
characteristics and 5-year oncologic outcomes were compared in
the 2 sex groups.
Survival curves were analyzed using the Kaplan–Meier
method, and statistical signiﬁcance was determined using the
log-rank test. Signiﬁcance of survival variables was analyzed by
the stepwise Cox proportional hazards model. Univariate Cox
regression analysis determined the correlation between each
variable and RFS. Multivariate Cox regression analysis assessed
whether sex was independently associated with RFS. P-values
<.05 were considered statistically signiﬁcant. All data were
processed and statistically analyzed using IBM SPSS Statistics for
Windows, version 23.0. (IBM Corp., Armonk, NY).
3. Results
3.1. Patient characteristics
Table 1 shows the clinicopathologic characteristics of the patients
according to sex. Male patients underwent more total thyroidecto-
mies with CCND and lateral neck dissection than women (16.4 vs
11.2%; P< .001). The median tumor size was larger (0.8 [0.5–1.2]
vs 0.7 [0.5–1.1]cm; P< .001), and the median numbers of retrieved
Table 1
Clinicopathologiccharacteristicsofstudypatientsaccording tosex.
Male Female P value
No. of patients 1232 7276
Age, y 45 (38–55) 46 (37–54) .404
Radiation history 5 (0.4) 24 (0.3) .376
Family history 135 (10.1) 737 (10.1) .375
Type of surgery <.001
LTT+CCND 433 (35.1) 2780 (38.2)
TT+CCND 598 (48.5) 3681 (50.6)
TT+CCND+LND 201 (16.4) 815 (11.2)
Hospital stay, d 3 (3–4) 3 (3–4) .546
Tumor size, cm 0.8 (0.5–1.2) 0.7 (0.5–1.1) <.001
Extrathyroidal extension, n (%) 634 (51.5) 3854 (53.0) .325
Multiplicity, n (%) 25 (9.3) 156 (10.4) .427
Bilaterality, n (%) 256 (20.8) 1518 (20.9) .083
Total retrieved nodes 4 (2–9) 5 (2–9) .374
Central nodes 4 (2–7) 5 (3–8) .001
Lateral nodes 29 (20–46) 23 (8–33) <.001
Total positive nodes 0 (0–3) 0 (0–1) <.001
Central nodes 1 (0–2) 0 (0–1) <.001
Lateral nodes 4 (1–8) 2 (0–5) <.001
T classiﬁcation, n (%) .893
T1 568 (46.1) 3355 (46.1)
T2 17 (1.4) 65 (0.9)
T3 622 (50.5) 3714 (51.0)
T4 25 (2.0) 142 (2.0)
N classiﬁcation, n (%) <.001
N0 620 (50.3) 4737 (65.1)
N1a 436 (35.4) 1933 (25.6)
N1b 176 (14.3) 604 (8.3)
M classiﬁcation, n (%) .227
M0 1227 (99.6) 7263 (99.8)
M1 5 (0.4) 13 (0.2)
TNM stage, n (%) .167
I 798 (64.8) 4804 (66.0)
II 7 (0.6) 13 (0.2)
III 340 (27.6) 2122 (29.2)
IV 87 (7.1) 337 (4.6
Pathology, n (%) .035
PMC 753 (61.1) 4994 (68.6)
Conventional PTC 408 (33.1) 1907 (26.2)
Follicular variant 58 (4.7) 334 (4.6)
Columnar variant 0 (0) 2 (0.02)
Diffuse sclerosing variant 6 (0.5) 29 (0.4)
Tall cell variant 0 (0) 1 (0.01)
Insular variant 0 (0) 2 (0.02)
Other 7 (0.6) 7 (0.1)
Postoperative RAI ablation
n (%) 715 (58.0) 3986 (54.8) .032
Mean dose (mCi) 30 (0–30) 30 (0–30) <.001
CCND= central compartment neck dissection, cm= centimeter, LND= lateral neck dissection, LTT=
less than total thyroidectomy, mCi=millicurie, PMC=papillary microcarcinoma, PTC=papillary
thyroid carcinoma, RAI= radioactive iodine, TNM= tumor-nodes-metastasis, TT= total thyroidect-
omy.
Table 2
Analysis of patients with tumor recurrence according to sex.
Male Female P value
No. of patients 21 87
Age, y 45.6±18.6 44.7±15.9 .456
Type of surgery, n (%) .342
LTT+CCND 2 24
TT+CCND 8 34
TT+CCND+LND 11 29
Tumor size, cm 1.5±1.1 1.4±1.0 .628
Extrathyroidal extension, n (%) 16 (76.2) 67 (77.0) .937
Multiplicity, n (%) 3 (14.3) 15 (17.2) .747
Bilaterality, n (%) 8 (38.1) 32 (36.8) .912
Positive nodes 9.9±10.3 6.7±9.1 .193
Central nodes 5.2±7.4 3.8±3.8 .438
Lateral nodes 8.8±4.9 7.6±6.8 .588
T classiﬁcation, n (%) .965
T1 5 (23.8) 20 (23.0)
T2 0 (0) 0 (0)
T3 14 (66.7) 61 (70.1)
T4 2 (9.5) 6 (6.9)
N classiﬁcation, n (%) .067
N0 2 (9.5) 19 (21.8)
N1a 8 (38.1) 40 (46.0)
N1b 11 (52.4) 28 (32.2)
M classiﬁcation, n (%) .842
M0 18 (85.7) 76 (87.4)
M1 3 (14.3) 11 (12.6)
TNM stage, n (%) .721
I 11 (52.4) 43 (49.5)
II 2 (9.5) 3 (3.4)
III 3 (14.3) 21 (24.1)
IV 5 (23.8) 20 (23.0)
Postoperative RAI ablation
n (%) 20 (95.2) 64 (73.6) <.001
Mean dose 91.4±66.7 52.0±63.1 .012
Ablation success based on DxWBS, n (%) 18 (90.0) 50 (78.1) .769
Recur-free duration, mo 62.8±11.7 61.1±15.9 .650
Recur site, L: D: L+D 16: 4: 0 70: 14: 1 .911
Treatment modality, OP: RAI 15: 5 64: 18 .897
Serum Tg after 5 years (without TSH↑), ng/mL 8.9±29.2 38.8±172.7 .456
CCND=central compartment neck dissection, cm= centimeter, D=distant, L= local, LND= lateral
neck dissection, LTT= less than total thyroidectomy, OP= operation, RAI= radioactive iodine, Tg=
thyroglobulin, TNM= tumor-nodes-metastasis, TSH= thyroid-stimulating hormone, TT= total thyr-
oidectomy.
Kim et al. Medicine (2019) 98:19 www.md-journal.comcentral (4 [2–7] vs 5 [3–8]; P= .001) and lateral neck nodes (29 [20–
46] vs 23 [8–33]; P< .001) were higher in men. Furthermore, male
patients had greater numbers of positive central (1 [0–2] vs 0 [0–1];
P< .001) and lateral necknodes (4 [1–8] vs 2 [0–5];P< .001),which
resulted in signiﬁcantlymore frequentN1a andN1b stage tumors in
male patients (49.7 vs 33.9%; P< .001). After surgery, larger
number of male patients received RAI treatment (58.0 vs 54.8;
P= .032). HighermedianRAI dosewas applied tomale patients (30
[0–30] vs 30 [0–30]mCi; P< .001) (Table 1).3The median follow-up duration was 58 (range, 50–102)
months. One hundred ﬁve male patients and 392 female patients
were lost to follow-up.3.2. Oncologic outcomes
The ablation success rates based on diagnostic whole-body scans
were similar in the matched groups (95.7 vs 95.6%; P= .746). The
TSH-suppressed serum Tg concentrations at 5 years after ablation
were also similar (3.2±13.6 vs 3.7±24.9ng/mL;P= .593).During
the follow-up, 21 male and 87 female patients experienced tumor
recurrence. The recurrence rates over 5 years were not signiﬁcantly
different between the 2 groups (1.7% vs 1.0%; P= .531). Patients
with recurrence showed similar clinicopathologic features, recur-
rence-free period, site of recurrence, treatment modality, and
serumTg concentration at 5 years (Table 2). There was no disease-
speciﬁc mortality during the follow-up period.
Figure 1. Kaplan–Meier estimates of recurrence-free survival in (A) all patients and (B) hemithyroidectomy patients according to sex.
Kim et al. Medicine (2019) 98:19 MedicineThe 5-year median RFS did not differ signiﬁcantly between the
2 groups (55.7±17.8 vs 59.0±17.9 months; P= .118) (Fig. 1A).
3.3. Recurrence-free survival (RFS) analysis
Univariate survival analyses were performed to determine the
correlations between sex and other clinicopathological character-
istics and RFS. No difference in RFS was found betweenmale and
female patients (hazard ratio [HR] 1.529, 95% conﬁdence
interval [CI] 0.949–2.463). Subsequently, multiple Cox survival
analyses were performed for RFS to show that mean tumor sizeTable 3
Stepwise Cox regression analysis of PTC patients.
Univariate analysis
Hazard ratio 95% CI
Sex (male vs female) 1.529 (0.949–2.463)
Age, y 0.988 (0.972–1.004)
Family history 0.727 (0.421–1.255)
Type of surgery
TT vs LTT 0.271 (0.164–0.446)
TT+LND vs LTT 0.286 (0.185–0.442)
Tumor size, cm 1.721 (1.503–1.970)
Extrathyroidal extension 0.352 (0.225–0.550)
Multiplicity 1.547 (0.932–2.566)
Bilaterality 0.495 (0.335–0.732)
Positive nodes
Central nodes 1.185 (1.151–1.220)
Lateral nodes 1.085 (1.050–1.120)
TNM stage
2 vs 1 0.180 (0.112–0.239)
3 vs 1 3.139 (1.198–8.222)
4 vs 1 0.171 (0.097–0.299)
PTC subtype
PMC vs conventional 1.195 (0.542–2.636)
Others vs conventional 0.456 (0.206–1.010)
RAI abrasion treatment 1.011 (1.007–1.014)
cm= centimeter, LND= lateral neck dissection, LTT= less than total thyroidectomy, PMC=papillary
metastasis, TT= total thyroidectomy.
4was associated with RFS. Sex was not an independent predictor
of RFS (Table 3).3.4. Subanalyses of patients treated with
hemithyroidectomy
Further assessment of the PTC patients who underwent hemi-
thyroidectomy from January 2007 to December 2010 was
conducted. As a result, male patients were found to be older (44
[37–52] vs 42 [35–50] years; P= .007). The median number of
retrieved central neck nodes was higher in female patients (3 [2–Multivariate analysis
P value Hazard ratio 95% CI P value
.081 1.517 (0.616–3.736) .365
.150
.252
<.001 NA
<.001 NA
<.001 1.306 (1.003–1.701) .047
<.001 0.310 (0.092–1.049) .060
.091
.001 0.754 (0.369–1.541) .439
<.001 1.063 (0.996–1.134) .067
<.001 1.026 (0.974–1.080) .339
<.001 0.546 (0.258–1.155) .113
.020 NA
<.001 0.401 (0.084–1.913) .252
.658
.053
.011 0.998 (0.992–1.004) .585
microcarcinoma, PTC=papillary thyroid carcinoma, RAI= radioactive iodine, TNM= tumor-nodes-
Table 4
Clinicopathologic characteristics of hemithyroidectomy patients
according to sex.
Male Female P value
No. of patients 269 1509
Age, y 44 (37–52) 42 (35–50) .007
Radiation history 0 (0) 3 (0.2) .465
Family history 26 (9.6) 143 (9.5) .950
Hospital stay, d 3 (3–3) 3 (3–3) .113
Tumor size, cm 0.5 (0.4–0.7) 0.5 (0.3–0.7) .008
Extrathyroidal extension, n (%) 77 (28.5) 460 (30.6) .432
Multiplicity, n (%) 25 (9.3) 156 (10.4) .580
Retrieved central nodes 3 (2–6) 4 (2–7) .002
Positive central nodes 0 (0–1) 0 (0–0) <.001
T classiﬁcation, n (%) .384
T1 192 (71.4) 1032 (68.4)
T2 0 (0) 10 (0.7)
T3 77 (28.6) 466 (30.9)
T4 0 (0) 1 (0)
N classiﬁcation, n (%) <.001
N0 187 (69.5) 1222 (81.0)
N1a 82 (30.5) 287 (19.0)
TNM stage, n (%) .161
I 212 (78.8) 1245 (82.5)
II 0 (0) 2 (0.1)
III 57 (21.2) 262 (17.4)
IV 0 (0) 0 (0)
Pathology, n (%) .600
PMC 243 (90.3) 1378 (91.3)
Conventional PTC 10 (3.7) 56 (3.7)
Follicular variant 16 (6.0) 75 (5.0)
cm= centimeter, PMC=papillary microcarcinoma, PTC=papillary thyroid carcinoma, TNM= tumor-
nodes-metastasis.
Table 5
Analysis of hemithyroidectomy patients with tumor recurrence
according to sex.
Male Female P value
No. of patients 2 8
Age, y 39.0±0.0 38.6±11.7 .967
Tumor size, cm 1.0±0.0 0.5±0.5 .242
Extrathyroidal extension, n (%) 1 (50.0) 6 (75.0) .545
Multiplicity, n (%) 1 (50.0) 1 (12.5) .189
Positive central nodes 3.0±2.8 1.0±1.8 .252
T classiﬁcation, n (%) .545
T1 1 (50.0) 2 (25.0)
T2 0 (0) 0 (0)
T3 1 (50.0) 6 (71.0)
T4 0 (0) 0 (0)
N classiﬁcation, n (%) .011
N0 0 (0) 5 (65.1)
N1a 2 (100) 3 (25.6)
M classiﬁcation, n (%) .842
M0 18 (85.7) 76 (87.4)
M1 3 (14.3) 11 (12.6)
TNM stage, n (%) .486
I 2 (100) 6 (66.0)
II 0 (0) 0 (0)
III 0 (0) 2 (29.2)
IV 0 (0) 0 (0)
Recur-free duration, mo 76.5±24.7 55.0±10.7 .075
Recur site, L: D: L+D 2: 0: 0 8: 0: 0 >.999
Treatment modality, OP: RAI 2: 0 8: 0 >.999
Serum Tg after 5 years (without TSH↑), ng/mL 0.5±0.7 2.8±6.7 .643
cm= centimeter, D=distant, L= local, OP= operation, RAI= radioactive iodine, Tg= thyroglobulin,
TNM= tumor-nodes-metastasis, TSH= thyroid-stimulating hormone.
Kim et al. Medicine (2019) 98:19 www.md-journal.com6] vs 4 [2–7]; P= .002), whereas male patients had a greater
number of positive central neck nodes (0 [0–1] vs 0 [0–0];
P< .001), and consequently more frequent N1a stage tumors
(30.4 vs 19.0%; P< .001) (Table 4).
Recurrence was detected in 2 male and 8 female patients after 5
years. The recurrence rates were similar in the 2 groups (0.7 vs
0.5%; P= .672). Patients with recurrence had similar clinico-
pathologic features, postoperative RAI treatment, recurrence-free
period, site of recurrence, treatment modality, and serum Tg
concentration after 5 years (Table 5).Table 6
Stepwise Cox regression analysis of hemithyroidectomy patients.
Univariate analysis
Hazard ratio 95% CI
Sex (male vs female) 1.267 (0.262–6.037)
Age, y 0.955 (0.897–1.017)
Family history 0.266 (0.068–1.036)
Tumor size, cm 1.575 (0.593–4.184)
Extrathyroidal extension 0.184 (0.048–0.711)
Multiplicity 0.585 (0.119–2.869)
Positive nodes
Central nodes 1.405 (1.095–1.802)
TNM stage
Others vs1 0.808 (0.171–3.805)
PTC subtype
Others vs conventional 1.229 (0.154–9.384)
cm= centimeter, PTC=papillary thyroid carcinoma, TNM= tumor-nodes-metastasis.
5The 5-year median RFS showed no signiﬁcant difference
between the 2 groups (54.2±18.5 vs 66.0±16.9 months;
P= .676) (Fig. 1B).
Univariate and multiple Cox regression analyses were repeated
for hemithyroidectomy patients. Univariate analysis revealed no
difference in RFS between male and female patients (HR 1.327,
95% CI 0.278–6.323). Multivariate Cox survival analyses
showed that the number of positive central neck nodes was an
independent predictor of RFS, whereas sex was not an
independent predictor of RFS (Table 6).Multivariate analysis
P value Hazard ratio 95% CI P value
.775 1.305 (0.295–6.567) .747
.154
.056
.326
.014 0.246 (0.059–1.014) .052
.509
.007 1.314 (1.007–1.714) .044
.787
.846
Kim et al. Medicine (2019) 98:19 MedicineTo investigate the appropriate cutoff tumor size that yields
similar nodal status in hemithyroidectomy patients, the chi-
square test was performed for sex and N stage in all ﬁnal
pathologic tumor sizes. A tumor size 0.25cm was signiﬁcantly
associated with the similar nodal status between the 2 sex groups.
Moreover, we compared pathological N1a (pN1a) patients
who received hemithyroidectomy. Eighty-two male and 161
female patients were analyzed and showed similar rates of LN
micrometastases according to preoperative staging US (79.3 vs
81.7%; P= .962). US also revealed similar sizes of suspicious LNs
in the 2 groups (0.5±0.2 vs 0.6±0.2cm; P= .203).4. Discussion
Thyroid cancer is one of the most common endocrine
malignancies; it shows notable sex disparities, with a higher
incidence in women and worse prognosis in men.[8,10–12,22] The
sex difference in incidence is remarkable in DTCs, such as PTC
and FTC, for which the incidence is 3 times higher in women than
in men.
PTC is the most common histologic type, accounting for
approximately 80% of cases. Its incidence has nearly doubled in
the last few decades, contributing to the remarkable increase in
the overall thyroid cancer incidence worldwide.[9] While this may
be due to the earlier diagnosis of subclinical disease,[23] little is
currently known about the factors responsible for the dramatic
increase in PTC.
Investigations regarding the causes of these sex disparities have
been conducted previously. Radiation exposure[24] and dietary
iodine,[25] well-known environmental risk factors for thyroid
cancer, do not appear to account for these disparities. Clinical
and epidemiologic studies have provided no consistent evidence
regarding common somatic genetic alterations such as BRAF
V600E, that are rearranged in transformation/papillary thyroid
carcinomas, or neurotrophin receptor tyrosine kinase 1 muta-
tions contributing to the thyroid cancer sex differences.[26,27]
Recent studies have suggested that the estrogen and estrogen
hormone receptor status in thyroid cancer cells may promote cell
proliferation in thyroid cancer; however, there is no conclusive
evidence to conﬁrm the correlation between sex hormones and
these disparities.[28,29]
Male sex was associated with a higher mortality and lower
disease-free survival in most previous studies, and men show
worse OS and disease-speciﬁc survival (DSS) with more
recurrence.[30–39] Meanwhile, other studies have shown no sex
differences, presenting with the unaffected OS and DSS.[30,36,40–
42] Thus, a male survival disadvantage is not a consistent ﬁnding,
and the impact of sex on recurrences of DTC is not yet
substantiated.
Herein, we analyzed and compared the clinicopathologic
characteristics and oncologic outcomes of male and female PTC
patients. The study period included PTC patients from 2007 to
2010 for 2 reasons: to involve cases representative of the recent
trends in PTC, and to assess the 5-year oncologic outcomes.
Moreover, the stepwise Cox proportional hazards model was
created to evaluate signiﬁcant survival variables. First, univariate
Cox regression analysis identiﬁed the correlations between each
variable and RFS. Second, multivariate Cox regression analysis
was performed to discover whether sex was independently
associated with RFS.
Our analyses revealed that male PTC patients had signiﬁcantly
more LN metastases than females, both in the central and lateral6neck areas. However, despite the different nodal statuses, the 2
groups showed similar 5-year median RFS. Sex was not an
independent prognostic factor for tumor recurrence. According
to our data, tumor size was associated with prognosis of PTC,
and the number of positive central nodes had prognostic capacity
in hemithyroidectomy patients.
Tumor size was traditionally considered a prognostic factor for
disease recurrence, and the extent of surgery as well as RAI
treatment after surgery is largely determined by tumor size. PTCs
were generally divided into PMC and conventional PTC on the
basis of a tumor diameter of 1.0cm. However, the previous
studies have reported controversial recurrence rates according to
tumor size cutoff of 1.0cm. Recent studies provide the optimal
tumor size cutoff of 1.8 to 2.0cm for predicting the risk of
recurrence.[43,44] Moreover, many international groups have also
revealed the prognostic signiﬁcance of increasing number and
ratio of positive LNs in DTC.[45–47] These ﬁndings are
comparable to our study.
Although the reason for the similar RFS between male and
female PTC patients shown in this study remains difﬁcult to
explain, it may be partially due to the long-term trend of
decreasing prognostic potential of male sex. One study has
reported secular trends in the prognostic factors for PTC. The risk
for tumor recurrence associated with male sex decreased over
time, while the risk associated with pathologic characteristics
either remained the same or increased. Such results suggest that
the reasons behind this trend may be the change in clinical
characteristic of PTC and increased early detection of cancer in
male patients.[48]
In hemithyroidectomy patients, those with a tumor size of
0.25cmwere found to have similar N stages. Small-sized PMCs
rarely metastasize to the LNs, both in men and women. Thus,
early-stage thyroid cancers such as tiny PMC may not show
considerable sex difference in LN involvement. We furthermore
found that the 82 male and 161 female pN1a hemithyroidectomy
patients had similar rates of LNmicrometastases and similar sizes
of suspicious LNs. Male PTC patients may have more metastatic
potential to the LNs than females; however, the metastatic LNs
themselves may show similar cancer behaviors and traits,
especially in early-stage thyroid cancers.
This study has several limitations. First, the analysis was based
on a limited group of patients. Even with the existing indications
of total thyroidectomy and hemithyroidectomy, the early days of
thyroid surgery tend to be rather aggressive. In the early- and
mid-2000s, total thyroidectomywas predominantly performed in
thyroid cancer patients. Hence, our comparative analyses
involved patients treated from 2007, during which the number
of less than total thyroidectomies gradually increased. Second,
the study population was from a single center. Our institution
offers a well-developed screening program for thyroid cancer
patients, and a substantial amount of early-stage PTCs may have
been included. Moreover, we routinely perform prophylactic
ipsilateral CCND to all thyroid cancer patients. Results of this
study should be interpreted while considering these backgrounds.
Third, as PTC has a relatively favorable prognosis and mild
biological behavior, long-term follow-up data on the oncologic
outcomes are needed to validate our results.
Despite the aforementioned limitations, the present study is the
ﬁrst to compare the oncologic outcomes of PTC patients
according to sex. We believe that our study has provided some
novel viewpoints on current trends in male PTC patient
prognosis. The overall increasing incidence of PMC that suggests
Kim et al. Medicine (2019) 98:19 www.md-journal.comprompt diagnosis and treatment in the recent era should alert
clinicians to carefully consider the disease characteristics
themselves, not just sex differences. This study suggests that
aggressive pathologic factors have more impact on disease
prognosis than sex. The prognostic indicators for PTC, including
large tumor size or LN metastases, should be focused on to
provide proper treatment. Based on past statistical data, male sex
linked to more aggressive treatment can possibly be a fallacy of
generalization. Our results provide a good starting point to guide
future studies.5. Conclusion
Despite the higher metastatic potential for the LNs in male PTC
patients, sex was not an independent prognostic factor for tumor
recurrence. The similar oncologic outcomes and the similar traits
of metastatic LNs among men and women indicate that excessive
treatments in male PTC patients compared with females may not
be warranted, especially in cases of PMC. Multicenter clinical
studies with long-term follow-ups are needed to validate these
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